Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: results of a single-institution series with long-term follow-up.
Aged
Androgen Antagonists
/ therapeutic use
Chemotherapy, Adjuvant
Follow-Up Studies
Gonadotropin-Releasing Hormone
/ agonists
Humans
Induction Chemotherapy
Intestinal Perforation
/ etiology
Intraoperative Complications
/ etiology
Kaplan-Meier Estimate
Lymphocele
/ etiology
Male
Middle Aged
Neoplasm Staging
Postoperative Complications
/ etiology
Prostate-Specific Antigen
/ blood
Prostatectomy
/ methods
Prostatic Neoplasms
/ blood
Rectum
/ injuries
Retrospective Studies
Survival Rate
Time Factors
Urinary Bladder Neck Obstruction
/ etiology
#ProstateCancer
#pcsm
inductive androgen deprivation
inoperable high-risk prostate cancer
prostate-specific antigen nadir
radical prostatectomy
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
18
5
2018
medline:
21
8
2019
entrez:
18
5
2018
Statut:
ppublish
Résumé
To determine the outcomes of complete surgical resection of T4 prostate cancer after inductive androgen-deprivation therapy (ADT), as inductive ADT and subsequent radical prostatectomy (RP) is not recommended by any guideline yet. A monocentric RP database was queried for patients initially diagnosed with T4 prostate cancer, considered primarily as inoperable because of a fixed mass defined by rectal examination in combination with high PSA level and/or large foci of biopsy confirmed undifferentiated prostate cancer. Treatment consisted of primary ADT until PSA nadir with consecutive RP. Patients underwent retropubic RP (RRP) or robot-assisted laparoscopic RP (RALP) after inductive ADT until achievement of the PSA nadir, which is in general reached after 6-7 months. The intraoperative course and complications were analysed. Finally, Kaplan-Meier estimates were calculated for overall survival (OS) and prostate cancer-specific survival (PCSS). We retrospectively identified 116 patients treated between 2000 and 2014. At diagnosis, the median (range) PSA level was 37.6 (2.44-284) ng/mL. The preoperative median (range) PSA after inductive ADT was 0.73 (0.01-34) ng/mL. Thereafter, patients underwent RRP or, since 2006, RALP. The median (95% confidence interval) OS was 156 (118.9-193.1) months. The PCSS at 150 months was 82%. Surgical therapy of primarily inoperable prostate cancer is feasible and safe after inductive ADT. The OS of this cohort seems comparable with results described for patients with primary operable high-risk prostate cancer.
Substances chimiques
Androgen Antagonists
0
Gonadotropin-Releasing Hormone
33515-09-2
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Pagination
58-64Informations de copyright
© 2018 The Authors BJU International © 2018 BJU International Published by John Wiley & Sons Ltd.